Share

January 2022; 9 (1) ArticleOpen Access

Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders

Marius Ringelstein, Ilya Ayzenberg, Gero Lindenblatt, Katinka Fischer, Anna Gahlen, Giovanni Novi, Helen Hayward-Könnecke, Sven Schippling, Paulus S. Rommer, Barbara Kornek, Tobias Zrzavy, Damien Biotti, Jonathan Ciron, Bertrand Audoin, Achim Berthele, Katrin Giglhuber, Helene Zephir, Tania Kümpfel, Robert Berger, Joachim Röther, Vivien Häußler, Jan-Patrick Stellmann, Daniel Whittam, Anu Jacob, Markus Kraemer, Antoine Gueguen, Romain Deschamps, Antonios Bayas, Martin W. Hümmert, Corinna Trebst, Axel Haarmann, Sven Jarius, Brigitte Wildemann, Matthias Grothe, Nadja Siebert, Klemens Ruprecht, Friedemann Paul, Nicolas Collongues, Romain Marignier, Michael Levy, Michael Karenfort, Michael Deppe, Philipp Albrecht, Kerstin Hellwig, Ralf Gold, Hans-Peter Hartung, Sven G. Meuth, Ingo Kleiter, Orhan Aktas, on behalf of the Neuromyelitis Optica Study Group (NEMOS)
First published November 16, 2021, DOI: https://doi.org/10.1212/NXI.0000000000001100
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
2373

Share

Article Information

vol. 9 no. 1 e1100
DOI: 
https://doi.org/10.1212/NXI.0000000000001100
PubMed: 
34785575
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received February 8, 2021
  • Accepted in final form August 25, 2021
  • First Published November 16, 2021.
Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Marius Ringelstein, MD*,
    2. Ilya Ayzenberg, MD* (ilya.ayzenberg{at}ruhr-uni-bochum.de),
    3. Gero Lindenblatt, MD (g.lindenblatt{at}ak-neuss.de),
    4. Katinka Fischer, MSc (katinka.fischer{at}hhu.de),
    5. Anna Gahlen, MD (anna.gahlen{at}rub.de),
    6. Giovanni Novi, MD (giovanninovi{at}gmail.com),
    7. Helen Hayward-Könnecke, MD (helen.hayward-koennecke{at}triemli.zuerich.ch),
    8. Sven Schippling, MD (sven.schippling{at}roche.com),
    9. Paulus S. Rommer, MD (paulus.rommer{at}meduniwien.ac.at),
    10. Barbara Kornek, MD (barbara.kornek{at}meduniwien.ac.at),
    11. Tobias Zrzavy, MD (tobias.zrzavy{at}meduniwien.ac.at),
    12. Damien Biotti, MD (biotti.d{at}chu-toulouse.fr),
    13. Jonathan Ciron, MD (ciron.j{at}chu-toulouse.fr),
    14. Bertrand Audoin, MD (bertrand.audoin{at}ap-hm.fr),
    15. Achim Berthele, MD (achim.berthele{at}tum.de),
    16. Katrin Giglhuber, MD (katrin.giglhuber{at}mri.tum.de),
    17. Helene Zephir, MD (helene.zephir{at}chru-lille.fr),
    18. Tania Kümpfel, MD (tania.kuempfel{at}med.uni-muenchen.de),
    19. Robert Berger, MD (r.berger{at}asklepios.com),
    20. Joachim Röther, MD (j.roether{at}asklepios.com),
    21. Vivien Häußler, MD (v.haeussler{at}uke.de),
    22. Jan-Patrick Stellmann, MD (jan-patrick.stellmann{at}univ-amu.fr),
    23. Daniel Whittam, MD (daniel.whittam{at}nhs.net),
    24. Anu Jacob, MD (jacoba{at}clevelandclinicabudhabi.ae),
    25. Markus Kraemer, MD (markus.kraemer{at}krupp-krankenhaus.de),
    26. Antoine Gueguen, MD (agueguen{at}for.paris),
    27. Romain Deschamps, MD (rdeschamps{at}for.paris),
    28. Antonios Bayas, MD (antonios.bayas{at}klinikum-augsburg.de),
    29. Martin W. Hümmert, MD (huemmert.martin{at}mh-hannover.de),
    30. Corinna Trebst, MD (trebst.corinna{at}mh-hannover.de),
    31. Axel Haarmann, MD (haarmann_a{at}ukw.de),
    32. Sven Jarius, MD (sjarius{at}gmx.net),
    33. Brigitte Wildemann, MD (brigitte.wildemann{at}med.uni-heidelberg.de),
    34. Matthias Grothe, MD (matthias.grothe{at}uni-greifswald.de),
    35. Nadja Siebert, MD (nadja.siebert{at}charite.de),
    36. Klemens Ruprecht, MD (klemens.ruprecht{at}charite.de),
    37. Friedemann Paul, MD (friedemann.paul{at}charite.de),
    38. Nicolas Collongues, MD (nicolas.collongues{at}chru-strasbourg.fr),
    39. Romain Marignier, MD (romain.marignier{at}chu-lyon.fr),
    40. Michael Levy, MD (mlevy11{at}mgh.harvard.edu),
    41. Michael Karenfort, MD (michael.karenfort{at}med.uni-duesseldorf.de),
    42. Michael Deppe, PhD (deppe{at}uni-muenster.de),
    43. Philipp Albrecht, MD (phil.albrecht{at}gmail.com),
    44. Kerstin Hellwig, MD (k.hellwig{at}klinikum-bochum.de),
    45. Ralf Gold, MD (ralf.gold{at}rub.de),
    46. Hans-Peter Hartung, MD (hans-peter.hartung{at}uni-duesseldorf.de),
    47. Sven G. Meuth, MD (sven.meuth{at}uni-duesseldorf.de),
    48. Ingo Kleiter, MD* (ingo.kleiter{at}rub.de),
    49. Orhan Aktas, MD* (orhan.aktas{at}med.uni-duesseldorf.de);
    50. on behalf of the Neuromyelitis Optica Study Group (NEMOS)
  1. Marius Ringelstein, MD*,
    2. Scientific Advisory Boards:

    1. 1. Roche Pharma GmbH, served on a national scientific advisory board. 2. Alexion Pharma GmbH, served on a national scientific advisory board.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1. Alexion, speaking honorarium. 2. Roche,speaking honorarium and funding for travel to a conference. 3. Biogen Idec, funding for travel to a conference.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1. Roche Pharma GmbH, served on a national and international scientific advisory board. 2. Alexion Pharma GmbH, served on a national scientific advisory board.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Ilya Ayzenberg, MD* (ilya.ayzenberg{at}ruhr-uni-bochum.de),
    3. Scientific Advisory Boards:

    1. I took part in advisory boards of comercial pharmaceutrical companies Roche, Alexion, Merck.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. I received speaker honoraria from Roche, Alexion, Merck Santhera companies.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. I received research grant from Diamed Company.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Gero Lindenblatt, MD (g.lindenblatt{at}ak-neuss.de),
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Bayer Healthcare, travel reimbursement

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Katinka Fischer, MSc (katinka.fischer{at}hhu.de),
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Anna Gahlen, MD (anna.gahlen{at}rub.de),
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Sanofi Genzyme, travel reimbursement

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Giovanni Novi, MD (giovanninovi{at}gmail.com),
    7. Scientific Advisory Boards:

    1. (1) Served on a scientific advisory board for Merck and received speaker onoraria from Novartis and Roche

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Helen Hayward-Könnecke, MD (helen.hayward-koennecke{at}triemli.zuerich.ch),
    8. Scientific Advisory Boards:

    1. (1) Biogen (2) Sanofi (3) Novartis (4) TEVA (5) Bayer

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Bayer (2) Sanofi

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Sven Schippling, MD (sven.schippling{at}roche.com),
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Frontiers in Neurology (Neuroimmunology)

    Patents:

    1. Therapeutic vaccination against JC virus mediated PML using the capsid peptides (incl. but not exclusively VP1).

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. I am an employee of Roche Pharma Research & Early Development (pRED), Neuroscience and Rare Diseases (NRD), Basel, Switzerland.

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) Swiss National Science Foundation (SNF)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Myelin Repair Foundation (USA)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Paulus S. Rommer, MD (paulus.rommer{at}meduniwien.ac.at),
    10. Scientific Advisory Boards:

    1. Alexion, Roche, Sanofi Genzyme, Sandoz, Amicus

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Associate Editor : Frontiers in Neurology, Frontiers in Immunology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1) Merck 2) Roche 3) biogen 4) Amicus

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Barbara Kornek, MD (barbara.kornek{at}meduniwien.ac.at),
    11. Scientific Advisory Boards:

    1. Biogen, Sanofi-Genzyme, Merck, TEVA Aventis, Roche, BMS/Celgene, Novartis, Johnson&Johnson.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Travel honoraraia and honoraria for speaking from BMS/ Celgene, Merck, TEVA Aventis,Roche, Biogen, Sanofi-Genzyme, Novartis, Johnson&Johnson

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Tobias Zrzavy, MD (tobias.zrzavy{at}meduniwien.ac.at),
    12. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. Damien Biotti, MD (biotti.d{at}chu-toulouse.fr),
    13. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  13. Jonathan Ciron, MD (ciron.j{at}chu-toulouse.fr),
    14. Scientific Advisory Boards:

    1. Serving on Merck scientific board Serving on Roche scientific board Serving on Novartis scientific board Serving on Celgene scientific board Serving on Alexion scientific board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  14. Bertrand Audoin, MD (bertrand.audoin{at}ap-hm.fr),
    15. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  15. Achim Berthele, MD (achim.berthele{at}tum.de),
    16. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. I received funding for travel and speaker honoraria from Alexion, Biogen, and Roche.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. I have received consultancies from Alexion, Bayer Healthcare, Biogen, Celgene and Roche

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  16. Katrin Giglhuber, MD (katrin.giglhuber{at}mri.tum.de),
    17. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  17. Helene Zephir, MD (helene.zephir{at}chru-lille.fr),
    18. Scientific Advisory Boards:

    1. I received consulting fees from ROCHE, BIOGENIDEC, NOVARTIS, SANOFI, ALEXION.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. I received consultancies fees from BIOGENIDEC, MERCK, BAYER, NOVARTIS, SANOFI, GENZYME, TEVA

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. I received research support grants from ROCHE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. I received research support grants from Ligue Française contre la sclérose en plaques and from ARSEP (Association de recherche contre la Sclérose en plaques)

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  18. Tania Kümpfel, MD (tania.kuempfel{at}med.uni-muenchen.de),
    19. Scientific Advisory Boards:

    1. T. Kumpfel has served on advisory boards for Roche Pharma

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. T. Kumpfel has received personal compensations/speaker honoraria from Bayer Healthcare, Teva Pharma, Merck, Novartis Pharma, Sanofi-Aventis/Genzyme, Roche Pharma and Biogen as well as grant support from Novartis and Chugai Pharma in the past.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  19. Robert Berger, MD (r.berger{at}asklepios.com),
    20. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  20. Joachim Röther, MD (j.roether{at}asklepios.com),
    21. Scientific Advisory Boards:

    1. (1)Alexion(2)Boehringer Ingelheim(3)AstraZeneca(4)Bayer(5) Bristol Myers Squibb/Pfizer

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1)Alexion, speaker honoraria(2)Boehringer Ingelheim, speaker honoraria(3)AstraZeneca, speaker honoraria(4)Bayer, speaker honoraria(5)Bristol Myers Squibb/Pfizer, speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. (1)Alexion, speaker honoraria(2)Boehringer Ingelheim, speaker honoraria(3)Sanofi Aventis, speaker honoraria(4)Bayer, speaker honoraria(5)Bristol Myers Squibb/Pfizer, speaker honoraria

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  21. Vivien Häußler, MD (v.haeussler{at}uke.de),
    22. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  22. Jan-Patrick Stellmann, MD (jan-patrick.stellmann{at}univ-amu.fr),
    23. Scientific Advisory Boards:

    1. Commercial - Genzyme Commercial - Alexion

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Commercial - Genzyme

    Research Support, Government Entities:

    1. BMBF, German competence Network Multiple sclerosis’ (KKNMs). (FKZ 01GI1602c) 2016-2019

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  23. Daniel Whittam, MD (daniel.whittam{at}nhs.net),
    24. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  24. Anu Jacob, MD (jacoba{at}clevelandclinicabudhabi.ae),
    25. Scientific Advisory Boards:

    1. Novartis Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Viela Bio , Alexion Roche and Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Roche

    Speakers' Bureaus:

    1. Veila Bio, Novartis , Roche

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. UK NHS -NMO service

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  25. Markus Kraemer, MD (markus.kraemer{at}krupp-krankenhaus.de),
    26. Scientific Advisory Boards:

    1. MK received honoraria for educational activities from Roche Pharma and Chugai Pharma.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Markus Kraemer received honoriaria for educational activities from Roche Pharma and Chugai Pharma.

    Editorial Boards:

    1. Associate Editor of German DGNeurologie Journal.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  26. Antoine Gueguen, MD (agueguen{at}for.paris),
    27. Scientific Advisory Boards:

    1. Novartis Roche Merck Sanofi Alexon

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Roche Teva Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  27. Romain Deschamps, MD (rdeschamps{at}for.paris),
    28. Scientific Advisory Boards:

    1. (1) Alexion

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  28. Antonios Bayas, MD (antonios.bayas{at}klinikum-augsburg.de),
    29. Scientific Advisory Boards:

    1. (1) Merck Serono (2) Biogen (3) Novartis (4) TEVA (5) Sanofi/Genzyme (6) Roche (7) Alexion (8) Celgene (9) Janssen

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Merck Serono: travel, speaker honoraria, serving on scientific advisory boards (2) Biogen: travel, speaker honoraria, serving on scientific advisory boards (3) Novartis: travel, speaker honoraria, serving on scientific advisory boards (4) TEVA: travel, speaker honoraria, serving on scientific advisory boards (5) Sanofi/Genzyme: travel, speaker honoraria, serving on scientific advisory boards (6) Roche: speaker honoraria, serving on scientific advisory boards (7) Alexion: speaker honoraria, serving on scientific advisory boards (8) Celgene: travel, speaker honoraria, serving on scientific advisory boards (9) Janssen: serving on scientific advisory board

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Merck Serono (2) Biogen (3) Novartis (4) TEVA (5) Roche (6) Janssen

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  29. Martin W. Hümmert, MD (huemmert.martin{at}mh-hannover.de),
    30. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. The NEMOS cohort/NationNMO is supported by the German Ministry for Education and Research (BMBF) as part of the German Competence Network Multiple Sclerosis (KKNMS).

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  30. Corinna Trebst, MD (trebst.corinna{at}mh-hannover.de),
    31. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaker honoraria (educational efforts, CME activities) from Alexion Pharma Germany GmbH, Chugai Pharma Germany GmbH, and Roche Pharma GmbH

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  31. Axel Haarmann, MD (haarmann_a{at}ukw.de),
    32. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Alexion Pharmaceuticals, speaking fee.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  32. Sven Jarius, MD (sjarius{at}gmx.net),
    33. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  33. Brigitte Wildemann, MD (brigitte.wildemann{at}med.uni-heidelberg.de),
    34. Scientific Advisory Boards:

    1. Brigitte Wildemann served on scientific advisory boards for Novartis, Sanofi Genzyme, Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Brigitte Wildemann has received personal fees from Alexion, Biogen, Merck Serono, Sanofi Genzyme, Novartis,

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Brigitte Wildemann reports grants from Deutsche Forschungsgemeinschaft, Bundesministerium für Forschung und Technologie, grants from Dietmar Hopp Stiftung, grants from Klaus Tschira Stiftung, grants from Merck Serono, Novartis Pharmaceuticals, and from Sanofi Genzyme

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  34. Matthias Grothe, MD (matthias.grothe{at}uni-greifswald.de),
    35. Scientific Advisory Boards:

    1. (1) Celgene (2) Merck Serono (3) Novartis (4) Roche (5)Sanofi Genzyme

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Novartis, funding for converence (2) Roche, funding for converence (3) Biogen, funding for converence

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  35. Nadja Siebert, MD (nadja.siebert{at}charite.de),
    36. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. NS has received travel grants from Sanofi Genzyme, unrelated to the project.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  36. Klemens Ruprecht, MD (klemens.ruprecht{at}charite.de),
    37. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1)Bayer Healthcare, speaker honoraria (2)Guthy Jackson Charitable Foundation, travel honoraria

    Editorial Boards:

    1. (1) PLOS ONE, Academic Editor, since 2013

    Patents:

    1. NONE

    Publishing Royalties:

    1. (1) Neurologie in Frage und Antwort, Elsevier, 2000-2015

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis (2) Merck Serono

    Research Support, Government Entities:

    1. (1) German Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis) (2) European Union (821283-2)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Dr. med. Arthur Arnstein Foundation (2) Stiftung Charité (BIH Clinical Fellow)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  37. Friedemann Paul, MD (friedemann.paul{at}charite.de),
    38. Scientific Advisory Boards:

    1. Novartis OCTIMS study steering committee MedImmune / Viela Bio steering committee

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono, Alexion, Chugai, MedImmune, Shire, Roche, Actelion, Celgene

    Editorial Boards:

    1. Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. consultancies for SanofiGenzyme, BiogenIdec, MedImmune, Shire, Alexion

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion and Merck Serono

    Research Support, Government Entities:

    1. German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  38. Nicolas Collongues, MD (nicolas.collongues{at}chru-strasbourg.fr),
    39. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. N. Collongues serves on scientific advisory boards for and has received honoraria from Biogen Idec, Merck Serono, Sanofi-Genzyme, Bayer Schering Pharma, and Alexion Pharmaceutical.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  39. Romain Marignier, MD (romain.marignier{at}chu-lyon.fr),
    40. Scientific Advisory Boards:

    1. Dr Marignier is serving on a scientific advisory board of Viela Bio and UCB

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Romain Marignier has received lecturing fees and travel grants from Biogen, Novartis, Roche, Sanofi, Alexion, UCB

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  40. Michael Levy, MD (mlevy11{at}mgh.harvard.edu),
    41. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Elsevier - Multiple Sclerosis and Related Disorders

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Alexion, Genentech/Roche, Viela Bio

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. Neuromyelitis Optica Clinic - 20% effort Neuromyelitis Optica Research Lab - 80% effort

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH/NIAID R01AI130548

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  41. Michael Karenfort, MD (michael.karenfort{at}med.uni-duesseldorf.de),
    42. Scientific Advisory Boards:

    1. (1) Novartis advisory board

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaker Honorar from Novartis Pharma

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  42. Michael Deppe, PhD (deppe{at}uni-muenster.de),
    43. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  43. Philipp Albrecht, MD (phil.albrecht{at}gmail.com),
    44. Scientific Advisory Boards:

    1. (1) Novartis, serving on an advisory board; (2) Biogen, serving on an advisory board; (3) Ipsen, serving on an advisory board; (4) Merck, serving on an advisory board; (5) Merz, serving on an advisory board; (6) Roche, serving on an advisory board; (7) Allergan, serving on an advisory board; (8) Celgene, serving on an advisory board; (9) Janssen Cilag, serving on an advisory board;

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Novartis, travel/accommodation/meeting expenses and speaker honoraria; (2)Teva, travel/accommodation/meeting expenses and speaker honoraria; (3) Biogen, travel/accommodation/meeting expenses and speaker honoraria; (4) Merz Pharmaceuticals, travel/accommodation/meeting expenses, (5) Ipsen, travel/accommodation/meeting expenses; (6) Esai, travel/accommodation/meeting expenses; (7) Glaxo Smith Kline, travel/accommodation/meeting expenses; (8) Bayer Healthcare, speaker honoraria, travel/accommodation/meeting expenses; (9) Allergan, speaker honoraria, travel/accommodation/meeting expenses; (10) Celgene, travel/accommodation/meeting expenses; (11) (9) Merck, speaker honoraria, travel/accommodation/meeting expenses;

    Editorial Boards:

    1. (1) BMC Neuroscience, associate editor (2) Frontiers in Neurology, associate editor (3) Journal of Clinical Medicine, associate editor (4) Frontiers in Immunology, associate editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Biogen (2) Novartis (3) Merz Pharmaceuticals (4) Ipsen (5) Roche (6) Allergan (7) Celgene

    Research Support, Government Entities:

    1. European Fund For Regional Development (EFRE.NRW)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Doktor Robert Pfleger Stiftung (2) Iselore Luckow Stiftung (3) Europäischer Fonds für Forschung und Regionale Entwicklung (EFRE)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  44. Kerstin Hellwig, MD (k.hellwig{at}klinikum-bochum.de),
    45. Scientific Advisory Boards:

    1. (1) Novartis (2) Genzyme (3) Teva (4) Merck (5) Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Biogen, funding for travel (2) Novartis, funding for travel (3) Merck, funding for travel (4) Biogen Idec Germany, speaker honoraria (5) Teva, speaker honoraria (6) Sanofi Genzyme, speaker honoraria (7) Novartis, speaker honoraria (8) Bayer Healthcare, speaker honoraria (9) Merck Serono, speaker honoraria (10) Roche, speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. Honoraria from Biogen, Bayer Healthcare, Teva, Sanofi, Merck and Novartis

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen, Bayer Healthcare, Teva, Merck, Roche, Sanofi- Genzyme and Novartis

    Research Support, Government Entities:

    1. (1) Fund of the Federal Joint Committee

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  45. Ralf Gold, MD (ralf.gold{at}rub.de),
    46. Scientific Advisory Boards:

    1. (1) TEVA Laquinimod DSMB, AbbVie, Celgene

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaker honoraria from Biogen, Genzyme, TEVA, Merckserono, BayerSchering, Celgene, Novartis, Roche, Eisai

    Editorial Boards:

    1. SAGE Journal TAND, Experimental Neurology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. research support from Biogen, Genzyme, Merck and Novartis

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. From Roche From Merck From Bayer

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  46. Hans-Peter Hartung, MD (hans-peter.hartung{at}uni-duesseldorf.de),
    47. Scientific Advisory Boards:

    1. Novartis; Merck Serono; Teva; Biogen; Roche; Genzyme; BayerHealthcare; Sanofi; MedImmune; GeNeuro; Octapharma; BMS Celgene; Roche; CSL Behring; TG Therapeutics; Viela Bio /Horizon Therapeutics

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaker Honoraria from: Biogen Genzyme Merck Novartis Roche

    Editorial Boards:

    1. editorial board member (unpaid): CNS Drugs; Frontiers Neurology / Immunology; European Neurology; Journal of Clinical Medicine; Current Opinion in Neurology; Nature Reviews Neurology; Therapeutic Advances in Neurological Disorders; Journal of Neuroinflammation

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  47. Sven G. Meuth, MD (sven.meuth{at}uni-duesseldorf.de),
    48. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Sven G. Meuth received honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, and Teva.

    Editorial Boards:

    1. NONE

    Patents:

    1. Effectivity of specific FXII/FXIIa inhibitors, especially rHA-Infestin-4, in treating neuroinflammatory diseases(WO 2013/113774 A1 und EP 2 263 110 A1) Biomarkers for diagnosis and management of neuro-immunological diseases(WO 2016/028699 A2) NR2B selective NMDA-Receptor antagonists for treatment of immune-mediated inflammatory diseases (Reference number: PCT/EP2016/069975) Detection of anti-neurochondrin autoantibody in patients with cerebellar ataxia or cerebellitis (US10,112,982B2) Diagnosis of a novel autoimmune disease (EP086120B1; US2018/0298072,A1)

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. SGM's research is funded by Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, Merck Serono, Novartis, ONO Pharma, Roche, and Teva

    Research Support, Government Entities:

    1. SGM's research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), German Academic Exchange Service, Interdisciplinary Center for Clinical Studies (IZKF) Muenster

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. SGM's research is funded by the German Foundation Neurology, Hertie Foundation, Else Kroner Fresenius Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  48. Ingo Kleiter, MD* (ingo.kleiter{at}rub.de),
    49. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Alexion, Biogen, Celgene, Merck, Roche

    Editorial Boards:

    1. Associate editor for BMC Neurology, Editorial board member Neuroimmunology Reports

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Alexion, Biogen, Celgene, Merck, Roche

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  49. Orhan Aktas, MD* (orhan.aktas{at}med.uni-duesseldorf.de);
    50. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Bayer, speaker honoraria (2) Novartis, speaker honoraria (3) Biogen, travel and speaker honoraria (4) Merck Serono, travel and speaker honoraria (5) Teva, speaker honoraria (6) Sanofi-Genzyme, speaker honoraria (7) Roche, travel and speaker honoraria (8) Almirall, speaker honoraria (9) Alexion, travel and speaker honoraria (10) Celgene, travel and speaker honoraria (11) Viela Bio, travel support

    Editorial Boards:

    1. (1) PLoS ONE, Academic Editor, since 2012

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis

    Research Support, Government Entities:

    1. (1) German Ministry of Science (BMBF), PI for NationNMO/KKNMS (NationNMO‐PAT FKZ 01GI1602B), since 2016

    Research Support, Academic Entities:

    1. (1) German Research Foundation (DFG), PI in GRK2578, since 2020

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  50. on behalf of the Neuromyelitis Optica Study Group (NEMOS)
  1. Department of Neurology (M.R., K.F., M.K.,P.A., H.P.H., S.G.M., O.A.), Medical Faculty, Heinrich Heine University Düsseldorf; Department of Neurology (M.R.), Center for Neurology and Neuropsychiatry, LVR-Klinikum, Heinrich Heine University Düsseldorf; Department of Neurology (I.A., A.G., K.H., R.G., I.K.), St. Josef-Hospital, Ruhr University Bochum, Germany; Department of Neurology (I.A.), Sechenov First Moscow State Medical University, Russia; Department of Neurology (G.L.), Johanna Etienne Hospital, Neuss, Germany; Department of Neurology (G.N.), San Martino Hospital, Genova, Italy; Neuroimmunology and MS Research (H.H.K., S.S.), Department of Neurology, University Hospital Zürich, Switzerland; Department of Neurology (P.S.R., B.K., T.Z.), Medical University of Vienna, Austria; Department of Neurology (D.B., J.C.), B4 unit, CRC-SEP, Toulouse Purpan University Hospital, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) (D.B., J.C.) INSERM UMR1291-CNRS UMR5051 - Université Toulouse III, France; Aix Marseille University (B.A.), APHM, Hôpital de la Timone, Pôle de Neurosciences Cliniques, Service de Neurologie, Marseille, France; Technical University of Munich (A.B., K.G.), School of Medicine, Department of Neurology, Klinikum rechts der Isar, Germany; University of Lille (H.Z.), Inserm, CRC-SEP, CHU Lille, France; Institute of Clinical Neuroimmunology (T.K.), Faculty of Medicine, Ludwig Maximilian University, Munich; Department of Neurology (R.B., J.R.), Asklepios Klinik Altona, Hamburg; Department of Neurology and Institute of Neuroimmunology and MS (INIMS) (V.H.), University Medical Center Hamburg-Eppendorf, Germany; APHM, Hôpital de la Timone (J.P.S.), CEMEREM; Aix Marseille Univ, CNRS, CRMBM (J.P.S), UMR 7339, Marseille, France; Department of Neurology (D.W., A.J.), The Walton Centre, Liverpool, United Kingdom; the Cleveland Clinic Abu Dhabi, (A.J.) UAE; Department of Neurology (M.K.), Alfried Krupp Hospital, Essen, Germany; Department of Neurology (A.G.,R.D.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Department of Neurology (A.B.), Universitätsklinikum Augsburg; Department of Neurology (M.W.H., C.T.), Hannover Medical School; Department of Neurology (A.H.), University of Würzburg; Molecular Neuroimmunology Group (S.J., B.W.), Department of Neurology, University of Heidelberg; Department of Neurology (M.G.), University hospital Greifswald; NeuroCure Clinical Research Center and Experimental and Clinical Research Center (N.S., F.P), Max Delbrueck Center for Molecular Medicine and Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health; Department of Neurology (K.R.), Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin; Department of Neurology (N.C.), University Hospital Strasbourg; Service de neurologie (R.M.), sclérose en plaques, pathologies de la myéline et neuro-inflammation – Hôpital Neurologique Pierre Wertheimer Hospices Civils de Lyon, France; Department of Neurology (M.L.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of General Pediatrics (M.K.), Neonatology and Pediatric Cardiology, University Children's Hospital, Medical Faculty, Heinrich Heine University Düsseldorf; Department of Neurology (M.D.), University Hospital, Münster; and Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke, Berg, Germany.
  1. Correspondence
    Dr. Ringelstein marius.ringelstein{at}med.uni-duesseldorf.de or Dr. Aktas orhan.aktas{at}med.uni-duesseldorf.de
View Full Text

Article usage

Article usage: November 2021 to December 2022

AbstractFullPdfSource
Nov 202161375314Highwire
Dec 202129666256Highwire
Jan 2022480833343Highwire
Feb 2022433497227Highwire
Mar 2022147707208Highwire
Apr 202219398160Highwire
May 202228267115Highwire
Jun 202227273159Highwire
Jul 20222032098Highwire
Aug 20222728259Highwire
Sep 202240266115Highwire
Oct 202254282115Highwire
Nov 202235321126Highwire
Dec 20223816678Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

RELATED MULTIMEDIA

Related Articles

Topics Discussed

Alert Me